On Tuesday, Shares of Oasis Petroleum Inc. (NYSE:OAS), subtract -5.88% and closed at $10.87 in the last trading session. OAS stock opened its last trade at $11.20 and floating in a range of $10.52 to $11.39. The company’s Market capitalization is $1.94 Billion with the total Outstanding Shares of 180.43 million. During the 52-week trading session the minimum price at which share price traded, registered at $3.39 and reached to max level of $13.72.The Earnings per Share of the company stands at $ -0.68. Oasis Petroleum Inc. (OAS) (“Oasis” or the “Company”) declared recently that it has priced an upsized underwritten public offering of 48,000,000 shares of common stock for total gross proceeds (before the underwriters’ discounts and commissions and estimated offering expenses) of about $518.4 million. The Company intends to use the net proceeds from this offering to fund a portion of the formerly declared acquisition of SM Energy Company’s Bakken assets (the “Acquisition”). The offering is not conditioned on the consummation of the Acquisition, and if the Acquisition does not occur, the net proceeds will be used for general corporate purposes, which may include funding a portion of the Company’s 2017 capital budget. Oasis granted the underwriters a 30-day option to purchase up to 7,200,000 additional shares of common stock. The offering is expected to close on October 21, 2016.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD), added 1.06% and closed at $73.41 in the last trading session. GILD stock opened its last trade at $73.40 and floating in a range of $72.91 to $73.83. The company’s Market capitalization is $96.73 Billion with the total Outstanding Shares of 1.32 million. During the 52-week trading session the minimum price at which share price traded, registered at $72.21 and reached to max level of $111.11.The Earnings per Share of the company stands at $11.35. Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The companys products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, in addition to diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners.